Developer docs
API playgroundTry for free, no card

Search company profiles

BioPlan Associates

Full company profile

uuid000ko5w

Namestring
BioPlan Associates
Legal namestring
BioPlan Associates, Inc.
Company typeenum
Private
Founded yearint
1989
Descriptiontext

BioPlan Associates is a privately-held market analysis and strategy consulting firm founded in 1989 and headquartered in Rockville, Maryland. The company specializes in biopharmaceutical manufacturing intelligence, serving biopharma operators, CDMOs, single-use technology suppliers, equipment manufacturers, emerging biotechs, and private equity and strategic investors across global markets with emphasis on the US, Europe, China, and India. The firm positions itself as an independent, vendor-conflict-free source of validated primary research, with products and services designed to reduce decision risk for capital commitments, market entries, product launches, and acquisitions.

The company's core intellectual property is built on 30+ years of continuous biomanufacturing benchmarking. Proprietary database products include the Top1000Bio Facility Index (tracking 1,500+ global biopharma facilities), the Top200 Cell and Gene Therapy Facilities Database, the Top300 Bio CDMO Facilities Database, and the Top100 China Biomanufacturers Database. The flagship publication is the 22nd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (539 pages), supplemented by topical reports on China, India, expression systems, biosimilars, and clinical trials. Underlying these assets is a 750-member Biotechnology Industry Council of global decision-makers and a bench of 77 independent consultants that enable rapid primary research.

BioPlan generates revenue through four streams: (1) strategic advisory and consulting engagements (M&A due diligence, market entry strategy, technology adoption modeling, competitive threat assessment) delivered on a project basis; (2) annual and topical market research reports sold as digital PDFs and hardcover editions with global license options; (3) recurring subscriptions to proprietary databases with quarterly newsletters and analyst access; and (4) one-time book and publication sales. Pricing is not publicly disclosed; all products are sold via direct contact with sales. The firm has remained independently held without external funding since founding, operating as a bootstrapped consulting and research firm for over three decades.

Short descriptiontext

BioPlan Associates is a privately-held, independent biopharmaceutical market intelligence and strategy consulting firm founded in 1989, serving CDMOs, bioprocessing suppliers, pharma companies, and PE investors with proprietary facility databases, annual benchmark reports, and bespoke advisory engagements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharma market research, CDMO intelligence databases, biomanufacturing consulting, biopharma facility tracking, pharmaceutical strategy advisory
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Market Intelligence & Strategy Consulting
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic Advisory & Consulting
TypeProfessional Services
Description

Custom consulting engagements for M&A due diligence, market entry strategy, technology adoption modeling, and competitive threat assessment. Revenue generated through project-based professional services engagements with biopharma operators, investors, and CDMO leaders.

bioplanassociates.com
2Market Research Reports
TypeOne Time License
Description

Annual and topical reports including the flagship 22nd Annual Report of Biopharmaceutical Manufacturing Capacity and Production (539 pages). Reports available as digital PDFs and hardcover editions with global license options.

bioplanassociates.com
3Database Subscriptions
TypeSubscription Recurring
Description

Subscription-based access to Top1000Bio, Top200 Cell and Gene Therapy Facilities, Top300 CDMO Facilities, and regional databases (China Top 100, India Top 60). Includes quarterly newsletters and analyst access.

bioplanassociates.com
4Publications & Books
TypeOne Time License
Description

Sale of specialized books covering biopharmaceutical technology in China, India, expression systems, clinical trials guides, and market directories.

bioplanassociates.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Database Subscriptions - Contact for pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Contact for demo and pricing on Top1000Bio, Top200 Cell and Gene Therapy, Top300 CDMO, and China Top 100 databases

bioplanassociates.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioPlan Associates delivers strategic market intelligence and consulting services to the global biopharmaceutical industry through proprietary facility tracking databases, annual benchmarking reports, and custom research/advisory engagements. Their databases cover over 1,500 biopharma facilities, 400+ CDMO facilities, and 200+ cell/gene therapy facilities globally. Their flagship 22nd Annual Biomanufacturing Report is the longest-running industry benchmark study, supported by a 750-member Biotechnology Industry Council for primary research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Decision-risk reduction for high-stakes biopharma moves including capital commitments, market entries, product launches, and acquisitions
+2 more records
Product overview1 text field

BioPlan Associates is a consulting firm offering a portfolio of market intelligence products including specialized databases and advisory services. The core database products include the Top1000Bio Facility Index (tracking 1,500+ global biopharma facilities), Top200 Cell and Gene Therapy Facilities Database (200+ facilities), Top300 Bio CDMO Facilities Database (400+ contract manufacturing facilities), and Top100 China Biomanufacturers Database. These are complemented by flagship publications including the Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (539 pages), the Advances in Biopharmaceutical Technology in China report, the Growth of Biopharmaceutical Contract Manufacturing Organizations in China study, China Top Biopharmaceutical Manufacturing Directory, Top 60 Distributors of Bioprocessing Supplies in China, India Top 60 Biopharmaceutical Manufacturers Directory, Biopharmaceutical Expression Systems reference, Quick Guide to Clinical Trials, and Quick Guide to Healthcare and Biotechnology in the Middle East. Advisory services include custom market research (market sizing, forecasting, new product development, technology evaluation, pricing analysis, voice of customer) and strategic advisory consulting (M&A due diligence, market entry strategy, tech adoption modeling). The company also operates the Biotechnology Industry Council, a 750-member global decision-maker panel network.

Product and service17 records
1Top1000Bio Facility Index and Database
CategoryFacility Tracking Database
Description

Global biofacilities index and database subscription tracking over 1,500+ facilities worldwide manufacturing biopharmaceuticals, based on 30 years of industry evaluation and benchmarking. Used by biopharma operators and investors for facility-level competitive and market intelligence.

2Top200 Cell and Gene Therapy Facilities Database
CategoryFacility Tracking Database
Description

Global cell and gene therapy facilities database actively tracking over 200+ dedicated facilities providing cell therapy and gene therapy development and manufacturing services for biopharmaceuticals.

3Top300 Bio CDMO Facilities Database
CategoryFacility Tracking Database
Description

Comprehensive database of contract manufacturing tracking over 400+ bioprocessing facilities providing contract manufacturing services for biopharmaceuticals. Used by CDMOs and biopharma sponsors for capacity benchmarking and partnership identification.

4Top100 China Biomanufacturers Database
CategoryRegional Facility Tracking Database
Description

Comprehensive database of China's rapidly growing bioprocessing facilities, capacities, staffing, management, objectives, and market data. Designed for companies seeking to enter or expand in the Chinese biopharma market.

5Biopharmaceuticals in the US and European Markets Database
CategoryProduct Reference Database
Description

Encyclopedic monographs database covering all biopharmaceutical products including recombinant proteins, monoclonal antibodies, vaccines, enzymes, blood products, radioimmune conjugates, cultured cells and tissues. Authored by Ronald A. Rader.

6Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
CategoryIndustry Benchmarking Report
Description

Longest-running comprehensive study of bioprocessing professionals providing 539 pages of data-rich analysis on capacity, production trends, benchmarks, and industry outlook. The 22nd edition (2025) surveyed 203 companies, 116 vendors, and 21 countries. Available as digital PDF (Single-Office and Global License) and hardcover editions.

7Advances in Biopharmaceutical Technology in China
CategoryMarket Research Publication
Description

Peer-reviewed study incorporating research from over 100 global industry expert authors covering biopharmaceutical technology developments in China.

8Growth of Biopharmaceutical Contract Manufacturing Organizations in China
CategoryMarket Research Publication
Description

Comprehensive in-depth study providing detailed analysis of China's CMO industry, recent development, and trends, including profiles of CDMOs with capacity, history, products, and business strategies.

9China Top Biopharmaceutical Manufacturing Directory
CategoryIndustry Directory
Description

Directory of major biopharmaceutical manufacturing facilities in China covering facilities with the most bioprocessing capacity, including company ownership, management, capacity, and products.

10Top 60 Distributors of Bioprocessing Supplies in China
CategoryIndustry Directory
Description

Comprehensive directory providing detailed profiles of China's equipment and supply distributors industry with competitive landscape analysis.

11Directory of Top 60 Biopharmaceutical Manufacturers in India
CategoryIndustry Directory
Description

Directory with detailed profiles of Indian biopharmaceutical companies covering business focus, products, revenues, R&D, and international objectives.

12Biopharmaceutical Expression Systems
CategoryTechnical Reference Publication
Description

Reference covering new expression systems and improvements for commercial-scale manufacture of biopharmaceutical products, including platform technologies, prokaryotes, yeasts, mammals, and mammalian cell systems. Authored by Ronald A. Rader.

13Quick Guide to Clinical Trials
CategoryTextbook/Reference Publication
Description

Textbook resource covering clinical trial processes and drug development from an international perspective with 18 chapters written by industry experts.

14Quick Guide to Healthcare and Biotechnology in the Middle East
CategoryMarket Reference Publication
Description

Reference covering the Middle East regional pharmaceutical market valued at approximately US$10.6 billion, including healthcare industry investments and biotech opportunities.

15Custom Market Research
CategoryStrategic Advisory Service
Description

Primary-source intelligence including market sizing and forecasting, new product development, new technology evaluation, pricing and value quantification, and voice of customer research. Engagements conducted directly with biopharma operators, investors, and CDMO leaders.

16Strategic Advisory & Consulting
CategoryStrategic Advisory Service
Description

Advisory services supporting M&A committees, market-entry steering groups, and platform-investment decisions including due diligence, market entry strategy, and tech adoption modeling. Project-based engagements with biopharma operators, investors, and CDMO leaders.

17Biotechnology Industry Council
CategoryExpert Network Service
Description

750-member global decision-maker panel providing access to industry expertise and independent consultant bench for conducting research studies. Core differentiator enabling rapid primary research fielding for consulting engagements.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Standing panel of 750+ global decision-makers enabling primary research capabilities. Independent consultants and experts bench that allows rapid study fielding. Key differentiator for primary market intelligence gathering.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Market research and consulting firm with significant pharma/biotech practice covering bioprocessing, CDMOs, and biosimilars. Competes in syndicated market intelligence and strategic advisory across biopharma segments served by BioPlan.

TypeDirect peer
Description

Specialized market research firm focused on pharma, biotech, and healthcare markets with syndicated reports on biopharma manufacturing, cell therapy, and emerging modalities. Closely comparable to BioPlan's report-style offerings in scope and customer type.

TypeDirect peer
Description

Pharmaceutical product and business intelligence platform with proprietary databases on drugs, companies, and excipients. Comparable to BioPlan's biopharma intelligence database business, serving overlapping buyer personas in biopharma strategy and competitive intelligence.

TypeDirect peer
Description

Data and analytics company with extensive pharma/biopharma practice including proprietary databases, syndicated reports, and consulting. Competes across BioPlan's full service portfolio from facility intelligence to strategic advisory.

TypeBroad incumbent
Description

Massive life sciences analytics and services platform with broad portfolio of biopharma intelligence, R&D services, and commercial solutions. Overlaps with BioPlan's market intelligence while operating at much greater scale across the pharma value chain.

TypeDirect peer
Description

Global market intelligence and consulting firm with a deep life sciences practice covering biopharma manufacturing, CDMOs, and emerging modalities. Competes in syndicated pharma market research and strategic advisory engagements.

TypeDirect peer
Description

Biopharma intelligence platform from Informa providing databases, analytics, and reports across drug development, clinical trials, and commercialization. Directly competes with BioPlan's biopharma market intelligence offerings across syndicated research and advisory services.

8Mordor Intelligence
TypeDirect peer
Description

Market research firm covering pharma, biotech, and healthcare industries with syndicated reports and consulting. Overlaps directly with BioPlan's report and advisory offerings in biopharma market sizing and competitive analysis.

TypeDirect peer
Description

Pharma industry analysis platform offering consensus forecasts, deal intelligence, and company analysis for biopharmaceuticals. Overlaps with BioPlan's market sizing, competitive intelligence, and M&A due diligence services.

TypeBroad incumbent
Description

Scientific and IP intelligence company offering Cortellis for biopharma drug, clinical trial, and patent intelligence. Broad incumbent with biopharma specialization overlapping BioPlan's domain of decision-support intelligence.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile7 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioPlan Associates

Biopharmaceutical Market Intelligence & Strategy Consultingbioplanassociates.com

BioPlan Associates is a privately-held, independent biopharmaceutical market intelligence and strategy consulting firm founded in 1989, serving CDMOs, bioprocessing suppliers, pharma companies, and PE investors with proprietary facility databases, annual benchmark reports, and bespoke advisory engagements.

What BioPlan Associates does

BioPlan Associates is a privately-held market analysis and strategy consulting firm founded in 1989 and headquartered in Rockville, Maryland. The company specializes in biopharmaceutical manufacturing intelligence, serving biopharma operators, CDMOs, single-use technology suppliers, equipment manufacturers, emerging biotechs, and private equity and strategic investors across global markets with emphasis on the US, Europe, China, and India. The firm positions itself as an independent, vendor-conflict-free source of validated primary research, with products and services designed to reduce decision risk for capital commitments, market entries, product launches, and acquisitions.

The company's core intellectual property is built on 30+ years of continuous biomanufacturing benchmarking. Proprietary database products include the Top1000Bio Facility Index (tracking 1,500+ global biopharma facilities), the Top200 Cell and Gene Therapy Facilities Database, the Top300 Bio CDMO Facilities Database, and the Top100 China Biomanufacturers Database. The flagship publication is the 22nd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (539 pages), supplemented by topical reports on China, India, expression systems, biosimilars, and clinical trials. Underlying these assets is a 750-member Biotechnology Industry Council of global decision-makers and a bench of 77 independent consultants that enable rapid primary research.

BioPlan generates revenue through four streams: (1) strategic advisory and consulting engagements (M&A due diligence, market entry strategy, technology adoption modeling, competitive threat assessment) delivered on a project basis; (2) annual and topical market research reports sold as digital PDFs and hardcover editions with global license options; (3) recurring subscriptions to proprietary databases with quarterly newsletters and analyst access; and (4) one-time book and publication sales. Pricing is not publicly disclosed; all products are sold via direct contact with sales. The firm has remained independently held without external funding since founding, operating as a bootstrapped consulting and research firm for over three decades.

BioPlan Associates firmographics

Firmographics
Name
BioPlan Associates
Legal name
BioPlan Associates, Inc.
Website
https://bioplanassociates.com
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
1–10 employees
Short description
BioPlan Associates is a privately-held, independent biopharmaceutical market intelligence and strategy consulting firm founded in 1989, serving CDMOs, bioprocessing suppliers, pharma companies, and PE investors with proprietary facility databases, annual benchmark reports, and bespoke advisory engagements.
Ownership category
akta.pro rank

Where BioPlan Associates is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioPlan Associates business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Strategic Advisory & Consulting: Custom consulting engagements for M&A due diligence, market entry strategy, technology adoption modeling, and competitive threat assessment. Revenue generated through project-based professional services engagements with biopharma operators, investors, and CDMO leaders.
  2. Market Research Reports: Annual and topical reports including the flagship 22nd Annual Report of Biopharmaceutical Manufacturing Capacity and Production (539 pages). Reports available as digital PDFs and hardcover editions with global license options.
  3. Database Subscriptions: Subscription-based access to Top1000Bio, Top200 Cell and Gene Therapy Facilities, Top300 CDMO Facilities, and regional databases (China Top 100, India Top 60). Includes quarterly newsletters and analyst access.
  4. Publications & Books: Sale of specialized books covering biopharmaceutical technology in China, India, expression systems, clinical trials guides, and market directories.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualDatabase Subscriptions - Contact for pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

BioPlan Associates product offering

Product offering

Core offering

BioPlan Associates delivers strategic market intelligence and consulting services to the global biopharmaceutical industry through proprietary facility tracking databases, annual benchmarking reports, and custom research/advisory engagements. Their databases cover over 1,500 biopharma facilities, 400+ CDMO facilities, and 200+ cell/gene therapy facilities globally. Their flagship 22nd Annual Biomanufacturing Report is the longest-running industry benchmark study, supported by a 750-member Biotechnology Industry Council for primary research.

Product overview

BioPlan Associates is a consulting firm offering a portfolio of market intelligence products including specialized databases and advisory services. The core database products include the Top1000Bio Facility Index (tracking 1,500+ global biopharma facilities), Top200 Cell and Gene Therapy Facilities Database (200+ facilities), Top300 Bio CDMO Facilities Database (400+ contract manufacturing facilities), and Top100 China Biomanufacturers Database. These are complemented by flagship publications including the Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (539 pages), the Advances in Biopharmaceutical Technology in China report, the Growth of Biopharmaceutical Contract Manufacturing Organizations in China study, China Top Biopharmaceutical Manufacturing Directory, Top 60 Distributors of Bioprocessing Supplies in China, India Top 60 Biopharmaceutical Manufacturers Directory, Biopharmaceutical Expression Systems reference, Quick Guide to Clinical Trials, and Quick Guide to Healthcare and Biotechnology in the Middle East. Advisory services include custom market research (market sizing, forecasting, new product development, technology evaluation, pricing analysis, voice of customer) and strategic advisory consulting (M&A due diligence, market entry strategy, tech adoption modeling). The company also operates the Biotechnology Industry Council, a 750-member global decision-maker panel network.

Differentiator

Problem solved

Functional benefit

Products and services

  • Top1000Bio Facility Index and Database Global biofacilities index and database subscription tracking over 1,500+ facilities worldwide manufacturing biopharmaceuticals, based on 30 years of industry evaluation and benchmarking. Used by biopharma operators and investors for facility-level competitive and market intelligence.
  • Top200 Cell and Gene Therapy Facilities Database Global cell and gene therapy facilities database actively tracking over 200+ dedicated facilities providing cell therapy and gene therapy development and manufacturing services for biopharmaceuticals.
  • Top300 Bio CDMO Facilities Database Comprehensive database of contract manufacturing tracking over 400+ bioprocessing facilities providing contract manufacturing services for biopharmaceuticals. Used by CDMOs and biopharma sponsors for capacity benchmarking and partnership identification.
  • Top100 China Biomanufacturers Database Comprehensive database of China's rapidly growing bioprocessing facilities, capacities, staffing, management, objectives, and market data. Designed for companies seeking to enter or expand in the Chinese biopharma market.
  • Biopharmaceuticals in the US and European Markets Database Encyclopedic monographs database covering all biopharmaceutical products including recombinant proteins, monoclonal antibodies, vaccines, enzymes, blood products, radioimmune conjugates, cultured cells and tissues. Authored by Ronald A. Rader.
  • Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production Longest-running comprehensive study of bioprocessing professionals providing 539 pages of data-rich analysis on capacity, production trends, benchmarks, and industry outlook. The 22nd edition (2025) surveyed 203 companies, 116 vendors, and 21 countries. Available as digital PDF (Single-Office and Global License) and hardcover editions.
  • Advances in Biopharmaceutical Technology in China Peer-reviewed study incorporating research from over 100 global industry expert authors covering biopharmaceutical technology developments in China.
  • Growth of Biopharmaceutical Contract Manufacturing Organizations in China Comprehensive in-depth study providing detailed analysis of China's CMO industry, recent development, and trends, including profiles of CDMOs with capacity, history, products, and business strategies.
  • China Top Biopharmaceutical Manufacturing Directory Directory of major biopharmaceutical manufacturing facilities in China covering facilities with the most bioprocessing capacity, including company ownership, management, capacity, and products.
  • Top 60 Distributors of Bioprocessing Supplies in China Comprehensive directory providing detailed profiles of China's equipment and supply distributors industry with competitive landscape analysis.
  • Directory of Top 60 Biopharmaceutical Manufacturers in India Directory with detailed profiles of Indian biopharmaceutical companies covering business focus, products, revenues, R&D, and international objectives.
  • Biopharmaceutical Expression Systems Reference covering new expression systems and improvements for commercial-scale manufacture of biopharmaceutical products, including platform technologies, prokaryotes, yeasts, mammals, and mammalian cell systems. Authored by Ronald A. Rader.
  • Quick Guide to Clinical Trials Textbook resource covering clinical trial processes and drug development from an international perspective with 18 chapters written by industry experts.
  • Quick Guide to Healthcare and Biotechnology in the Middle East Reference covering the Middle East regional pharmaceutical market valued at approximately US$10.6 billion, including healthcare industry investments and biotech opportunities.
  • Custom Market Research Primary-source intelligence including market sizing and forecasting, new product development, new technology evaluation, pricing and value quantification, and voice of customer research. Engagements conducted directly with biopharma operators, investors, and CDMO leaders.
  • Strategic Advisory & Consulting Advisory services supporting M&A committees, market-entry steering groups, and platform-investment decisions including due diligence, market entry strategy, and tech adoption modeling. Project-based engagements with biopharma operators, investors, and CDMO leaders.
  • Biotechnology Industry Council 750-member global decision-maker panel providing access to industry expertise and independent consultant bench for conducting research studies. Core differentiator enabling rapid primary research fielding for consulting engagements.

Quantifiable outcome

  • Decision-risk reduction for high-stakes biopharma moves including capital commitments, market entries, product launches, and acquisitions
  • +2 more outcomes

Companies that use BioPlan Associates

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles7 records

BioPlan Associates technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BioPlan Associates partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Biotechnology Industry CouncilcoreOthersStanding panel of 750+ global decision-makers enabling primary research capabilities. Independent consultants and experts bench that allows rapid study fielding. Key differentiator for primary market intelligence gathering.

Scale indicators9 records

Recent moves5 records

Expansion highlights6 records

BioPlan Associates competitors and assessment

Company assessment

Direct peers

  • MarketsandMarkets: Market research and consulting firm with significant pharma/biotech practice covering bioprocessing, CDMOs, and biosimilars. Competes in syndicated market intelligence and strategic advisory across biopharma segments served by BioPlan.
  • Roots Analysis: Specialized market research firm focused on pharma, biotech, and healthcare markets with syndicated reports on biopharma manufacturing, cell therapy, and emerging modalities. Closely comparable to BioPlan's report-style offerings in scope and customer type.
  • PharmaCircle: Pharmaceutical product and business intelligence platform with proprietary databases on drugs, companies, and excipients. Comparable to BioPlan's biopharma intelligence database business, serving overlapping buyer personas in biopharma strategy and competitive intelligence.
  • GlobalData: Data and analytics company with extensive pharma/biopharma practice including proprietary databases, syndicated reports, and consulting. Competes across BioPlan's full service portfolio from facility intelligence to strategic advisory.
  • Frost & Sullivan: Global market intelligence and consulting firm with a deep life sciences practice covering biopharma manufacturing, CDMOs, and emerging modalities. Competes in syndicated pharma market research and strategic advisory engagements.
  • Citeline: Biopharma intelligence platform from Informa providing databases, analytics, and reports across drug development, clinical trials, and commercialization. Directly competes with BioPlan's biopharma market intelligence offerings across syndicated research and advisory services.
  • Mordor Intelligence: Market research firm covering pharma, biotech, and healthcare industries with syndicated reports and consulting. Overlaps directly with BioPlan's report and advisory offerings in biopharma market sizing and competitive analysis.
  • Evaluate: Pharma industry analysis platform offering consensus forecasts, deal intelligence, and company analysis for biopharmaceuticals. Overlaps with BioPlan's market sizing, competitive intelligence, and M&A due diligence services.

Broad incumbents

  • IQVIA: Massive life sciences analytics and services platform with broad portfolio of biopharma intelligence, R&D services, and commercial solutions. Overlaps with BioPlan's market intelligence while operating at much greater scale across the pharma value chain.
  • Clarivate: Scientific and IP intelligence company offering Cortellis for biopharma drug, clinical trial, and patent intelligence. Broad incumbent with biopharma specialization overlapping BioPlan's domain of decision-support intelligence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

BioPlan Associates social profiles

Digital presence

BioPlan Associates financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioPlan Associates leadership team

Management profile

Number of profiles

Profiles2 records

BioPlan Associates funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioPlan Associates M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioPlan Associates

What does BioPlan Associates do?

BioPlan Associates delivers strategic market intelligence and consulting services to the global biopharmaceutical industry through proprietary facility tracking databases, annual benchmarking reports, and custom research/advisory engagements. Their databases cover over 1,500 biopharma facilities, 400+ CDMO facilities, and 200+ cell/gene therapy facilities globally. Their flagship 22nd Annual Biomanufacturing Report is the longest-running industry benchmark study, supported by a 750-member Biotechnology Industry Council for primary research.

Is BioPlan Associates a public or private company?

BioPlan Associates is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioPlan Associates founded?

BioPlan Associates was founded in 1989. It employs 1 to 10 people.

Where is BioPlan Associates based?

BioPlan Associates is headquartered in Rockville, United States, in the North America region.

How does BioPlan Associates make money?

Four revenue lines are on record. Strategic Advisory & Consulting is the primary driver. The others are market Research Reports, database Subscriptions and publications & Books.

Who are BioPlan Associates's main competitors?

Direct peers on record are MarketsandMarkets, Roots Analysis, PharmaCircle, GlobalData, Frost & Sullivan, Citeline, Mordor Intelligence and Evaluate. Broad incumbents are IQVIA and Clarivate.

Does BioPlan Associates have an API?

No public API is recorded for BioPlan Associates.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ContractpharmaThe CDMO Capacity Crunch PersistsA 2026 survey by BioPlan Associates reveals that nearly half of biopharma companies face difficulties finding Contract Development and Manufacturing Organizations (CDMOs) with available capacity, particularly for advanced therapies like cell and gene therapy. While CDMOs are expanding their mammalian production capabilities to meet this demand, constraints persist due to hiring shortages, complex technical requirements, and rising costs associated with downstream purification. The industry is seeing a shift where sponsors prioritize technical fit and agility over simple availability, while emerging hubs in India and China capture increasing market share.BioplanassociatesBioPlan AssociatesThe article discusses the roles and expertise of Donnie E. Gillespie and Katrina Cordovado at BioPlan Associates, focusing on their research and strategic initiatives in healthcare and biomanufacturing. It highlights Hilton's management of industry analysis, network development, and global market research.BioProcess InternationalManaging Single-Use System Costs in BiomanufacturingAccording to BioPlan Associates' 21st annual biopharmaceutical manufacturing report, single-use systems (SUS) costs remain the top concern for bioprocessing professionals, with 32.3% identifying lower-cost devices as a priority and a persistent satisfaction gap of 46.4% between customer expectations and supplier delivery. The COVID-19 pandemic accelerated SUS adoption to over 87% of biomanufacturing facilities, but despite demand normalizing, high pricing continues while suppliers face mounting pressure to innovate beyond traditional bag-in-container designs and address sustainability challenges. With over 200 SUS suppliers now operating globally, industry growth in 2025 and beyond will depend on cost-efficiency, materials innovation, and integration with hybrid manufacturing environments.Bioprocess Online for bioanalytics21 New Downstream Technologies Being Considered To Fix Capacity ProblemsBioPlan Associates Inc. reports that 21 new downstream processing technologies are being considered by biopharmaceutical facilities to address capacity bottlenecks caused by increased upstream production. Continuous purification systems emerged as the top technology choice, with 37.7% of facilities planning to adopt continuous platforms to resolve these constraints. The industry is actively seeking alternatives to costly legacy protein A chromatography systems to improve efficiency and reduce operational expenses.BioplanassociatesBioPlan AssociatesBioPlan Associates has launched the Global Contract Development and Manufacturing Facilities Index and Database, which tracks over 400 dedicated CDMO facilities. The database provides quantitative analysis of biomanufacturing regions, including total bioreactor capacity and revenue estimates for clinical and commercial biologics CDMOs. This tool allows industry stakeholders to benchmark growth, identify partners, and analyze market competition within the biopharmaceutical sector.ContractpharmaTop 50 Biopharma Products Drive Growth in Contract ManufacturingBioPlan Associates' 2023 report indicates that CDMO revenues for biologics and vaccines reached $16.9 billion in 2022, driven by sustained demand and the industry's shift away from in-house production. The top-selling biopharmaceuticals, including Pfizer’s Comirnaty and AbbVie’s Humira, generated significant revenue, with the top 50 products accounting for 62.1% of the total market.ContractpharmaSymbiotic Success: How CDMOs Shaped a Decade of BiomanufacturingBioPlan Associates reports that the biopharmaceutical industry has increasingly relied on contract development and manufacturing organizations (CDMOs), with in-house production dropping from 57.6% in 2006 to 29.7% in 2023. The analysis highlights significant revenue growth for major CDMOs such as Lonza and WuXi Biologics, driven by biologics manufacturing and COVID-related activities, while noting a shift in outsourcing preferences away from China and India toward the U.S. and Germany.BioProcess InternationalPost-COVID Supply-Chain ChallengesBioPlan Associates and BioPhorum report that while demand for bioprocessing consumables remains strong, the post-pandemic landscape has shifted towards increased competition as end-users diversify suppliers to mitigate risks. Established suppliers are experiencing a decline in order volumes and revenue due to this multisourcing strategy, which allows buyers to leverage bargaining power and reduce prices. The industry is expected to normalize with more competitive pressures, though long-term growth trends driven by new biologics launches remain robust.DcatvciTop Biomanufacturing Trends for 2022BioPlan Associates reports that the biopharmaceutical industry is adapting to post-pandemic challenges, with a significant shift toward outsourcing and regionalization of manufacturing capacity. The survey highlights ongoing supply chain disruptions, labor shortages, and the rapid expansion of Contract Development and Manufacturing Organizations (CDMOs), particularly in Asia and Latin America.